Johnson & Johnson (NYSE:JNJ) has been on a roll. Thanks to a steady string of successful new drug launches, the company has beat analysts' earnings estimates in each of the past four quarters.

When Johnson reports earnings on July 15, investors will learn whether fast growth continued for key drugs including Zytiga, Xarelto, and Olysio.

In the following slideshow, you'll see what has been driving Johnson's success this past year and what you should be looking for in Johnson's release.